YaoGeJu

Company directoryChina company filings

Mu Yuan (Anhui) Pharma Co., Ltd. romanized

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference 0a901672a7

Complete CDE snapshot
2026/11/13 06:42
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/13 06:42.

Drug filings

13 acceptance records as first applicant, grouped into 8 source drug names. Source data as of 2026/11/13 06:42.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

Emedastine Difumarate Sustained-release Capsules 2 records · Latest accepted 2025/12/25

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2504381Generic2025/12/25Mu Yuan (Anhui) Pharma Co., Ltd. romanized; Hua Yi Tai Kang Pharma Co., Ltd. romanizedCDE ↗
CYHS2504379Generic2025/12/25Mu Yuan (Anhui) Pharma Co., Ltd. romanized; Hua Yi Tai Kang Pharma Co., Ltd. romanizedCDE ↗
Cefcapene Pivoxil Hydrochloride Granules 1 records · Latest accepted 2025/12/05

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2504185Generic2025/12/05Mu Yuan (Anhui) Pharma Co., Ltd. romanized; Shanxi Tong Da Pharma Co., Ltd. romanizedCDE ↗
Cefditoren Pivoxil Granules 2 records · Latest accepted 2025/08/06

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2502837Generic2025/08/06Mu Yuan (Anhui) Pharma Co., Ltd. romanized; Fu An Pharma Group Qing Yu Tang Pharmaceutical Co., Ltd. romanizedCDE ↗
CYHS2502836Generic2025/08/06Mu Yuan (Anhui) Pharma Co., Ltd. romanized; Fu An Pharma Group Qing Yu Tang Pharmaceutical Co., Ltd. romanizedCDE ↗
Mivacurium Chloride Injection 2 records · Latest accepted 2025/07/15

Supplement · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2501409Supplement2025/07/15Mu Yuan (Anhui) Pharma Co., Ltd. romanized; Chengdu Shi Hai Tong Pharma Co., Ltd. romanizedCDE ↗
CYHB2501408Supplement2025/07/15Mu Yuan (Anhui) Pharma Co., Ltd. romanized; Chengdu Shi Hai Tong Pharma Co., Ltd. romanizedCDE ↗
Hydrocortisone Sodium Succinate for Injection 2 records · Latest accepted 2025/06/04

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2501975Generic2025/06/04Mu Yuan (Anhui) Pharma Co., Ltd. romanized; Hainan He Rui Pharmaceutical Co., Ltd. romanizedCDE ↗
CYHS2501974Generic2025/06/04Mu Yuan (Anhui) Pharma Co., Ltd. romanized; Hainan He Rui Pharmaceutical Co., Ltd. romanizedCDE ↗
Benzbromarone Tablets 1 records · Latest accepted 2025/01/16

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2500325Generic2025/01/16Mu Yuan (Anhui) Pharma Co., Ltd. romanized; Huayi Pharmaceuticals (Anhui) Co., Ltd.CDE ↗
Azilsartan Medoxomil Potassium Tablets 2 records · Latest accepted 2025/01/14

Supplement · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2500088Supplement2025/01/14Mu Yuan (Anhui) Pharma Co., Ltd. romanized; Huayi Pharmaceuticals (Anhui) Co., Ltd.CDE ↗
CYHB2500087Supplement2025/01/14Mu Yuan (Anhui) Pharma Co., Ltd. romanized; Huayi Pharmaceuticals (Anhui) Co., Ltd.CDE ↗
Sulindac Tablets 1 records · Latest accepted 2024/09/06

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2402934Generic2024/09/06Mu Yuan (Anhui) Pharma Co., Ltd. romanized; Huayi Pharmaceuticals (Anhui) Co., Ltd.CDE ↗

Changes in the last 90 days

1 events from 2026/08/16 to 2026/11/13. CDE data as of 2026/11/13 06:42; NMPA data as of 2026/11/12 18:32.

This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Notification delivery: 1 application

  1. 2026/11/04Notification delivery

    Cefcapene Pivoxil Hydrochloride Granules

    CYHS2504185

    Fact date: 2026/11/04 (Publication date) · Publication date: 2026/11/04 · Site observation date: 2026/11/04

    Notification delivered; the specific outcome remains to be checked.

    View source · Table row 12 ↗

Under review

4 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/13 06:42.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Emedastine Difumarate Sustained-release Capsules CYHS2504381Generic2025/12/25Mu Yuan (Anhui) Pharma Co., Ltd. romanized; Hua Yi Tai Kang Pharma Co., Ltd. romanizedCDE ↗
Emedastine Difumarate Sustained-release Capsules CYHS2504379Generic2025/12/25Mu Yuan (Anhui) Pharma Co., Ltd. romanized; Hua Yi Tai Kang Pharma Co., Ltd. romanizedCDE ↗
Cefditoren Pivoxil Granules CYHS2502837Generic2025/08/06Mu Yuan (Anhui) Pharma Co., Ltd. romanized; Fu An Pharma Group Qing Yu Tang Pharmaceutical Co., Ltd. romanizedCDE ↗
Cefditoren Pivoxil Granules CYHS2502836Generic2025/08/06Mu Yuan (Anhui) Pharma Co., Ltd. romanized; Fu An Pharma Group Qing Yu Tang Pharmaceutical Co., Ltd. romanizedCDE ↗

Catalogue holder records

8 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/13 06:39. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerApproval numberApprovedCatalogue category (source text)View source
Mivacurium Chloride InjectionMu Yuan (Anhui) Pharma Co., Ltd. romanizedChengdu Shi Hai Tong Pharma Co., Ltd. romanized国药准字H202656972026/08/25Generic approved under the new chemical-drug registration classificationCDE ↗
Mivacurium Chloride InjectionMu Yuan (Anhui) Pharma Co., Ltd. romanizedChengdu Shi Hai Tong Pharma Co., Ltd. romanized国药准字H202656052026/08/04Generic approved under the new chemical-drug registration classificationCDE ↗
Benzbromarone TabletsMu Yuan (Anhui) Pharma Co., Ltd. romanizedHuayi Pharmaceuticals (Anhui) Co., Ltd.国药准字 H202644912026/05/19Generic approved under the new chemical-drug registration classificationCDE ↗
Sulindac TabletsMu Yuan (Anhui) Pharma Co., Ltd. romanizedHuayi Pharmaceuticals (Anhui) Co., Ltd.国药准字H202633152026/02/02Generic approved under the new chemical-drug registration classificationCDE ↗
Azilsartan Medoxomil Potassium TabletsMu Yuan (Anhui) Pharma Co., Ltd. romanizedHuayi Pharmaceuticals (Anhui) Co., Ltd.国药准字H202559972025/11/18Generic approved under the new chemical-drug registration classificationCDE ↗
Azilsartan Medoxomil Potassium TabletsMu Yuan (Anhui) Pharma Co., Ltd. romanizedHuayi Pharmaceuticals (Anhui) Co., Ltd.国药准字H202559982025/11/18Generic approved under the new chemical-drug registration classificationCDE ↗
Hydrocortisone Sodium Succinate for InjectionMu Yuan (Anhui) Pharma Co., Ltd. romanizedHainan He Rui Pharmaceutical Co., Ltd. romanized国药准字H202662772026/10/13Generic approved under the new chemical-drug registration classificationCDE ↗
Hydrocortisone Sodium Succinate for InjectionMu Yuan (Anhui) Pharma Co., Ltd. romanizedHainan He Rui Pharmaceutical Co., Ltd. romanized国药准字H202662762026/10/13Generic approved under the new chemical-drug registration classificationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

0 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/13 06:41.

NameCompany / applicantRegistration numberStatusSource update dateView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

0 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/13 06:42.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/13 06:42
Chemical-drug catalogue
Last successful update: 2026/11/13 06:39
Full API register
Last successful update: 2026/11/13 06:41
NMPA drug delivery notices
Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete

First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.